CytomX Therapeutics Inc.
Organization details
- Legal name
- CytomX Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CTMX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001501989
- EIN
- 27-3521219
Board of directors
-
Alan Ashworth · DirectorSince 2023
-
Charles S. Fuchs · DirectorSince 2026
-
Elaine Jones V · DirectorSince 2023
-
Halley E. Gilbert · DirectorSince 2023
-
James R. Meyers · DirectorSince 2023
-
Mani Mohindru · DirectorSince 2023
-
Matthew P. Young · DirectorSince 2023
-
Sean A. McCarthy · Director · CEOSince 2023
-
Zhen Su · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.3%
-
98.6%
Board connections
5 of this board's directors also sit on 7 other boards. 7 are in the same sector.
-
Arbutus Biopharma Corporation Same sectorvia James R. Meyers
-
Arcutis Biotherapeutics Inc. Same sectorvia Halley E. Gilbert
-
Cardiff Oncology Inc. Same sectorvia Mani Mohindru
-
Karyopharm Therapeutics Inc. Same sectorvia Zhen Su
-
NextCure Inc. Same sectorvia Elaine Jones V
-
Vaxcyte Inc. Same sectorvia Halley E. Gilbert
-
Vera Therapeutics Inc. Same sectorvia James R. Meyers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,231,578
- 5 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Carvajal Alejandra Officer (Chief Legal Officer) | Grant or award | +100,000 | — | — |
| Jun 15, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −1,624 | $3.05 | $4,953 |
| Mar 17, 2026 | Chu Yu-Waye Officer (Chief Medical Officer) | Open-market sale | −21,279 | $6.42 | $136,611 |
| Mar 17, 2026 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −118,969 | $6.42 | $763,781 |
| Mar 17, 2026 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Open-market sale | −31,492 | $6.42 | $202,179 |
| Mar 17, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −19,323 | $6.42 | $124,054 |
| Feb 2, 2026 | Lester Rachael Officer (Chief Business Officer) | Grant or award | +20,000 | — | — |
| Feb 2, 2026 | Chu Yu-Waye Officer (Chief Medical Officer) | Grant or award | +75,000 | — | — |
| Feb 2, 2026 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Grant or award | +60,000 | — | — |
| Feb 2, 2026 | Ogden Christopher Officer (Chief Financial Officer) | Grant or award | +90,000 | — | — |
| Feb 2, 2026 | Sean A. McCarthy Director, Officer (CEO) | Grant or award | +210,000 | — | — |
| Nov 6, 2025 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −101,793 | $4.54 | $462,140 |
| Jun 16, 2025 | BELVIN MARCIA Officer (SVP, Chief Scientific Officer) | Open-market sale | −13,884 | $2.69 | $37,348 |
| Jun 16, 2025 | Sean A. McCarthy Director, Officer (CEO) | Open-market sale | −55,511 | $2.69 | $149,325 |
| Jun 16, 2025 | Ogden Christopher Officer (Chief Financial Officer) | Open-market sale | −10,614 | $2.69 | $28,552 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about CytomX Therapeutics Inc.
Who is the CEO of CytomX Therapeutics Inc.?
Sean A. McCarthy is CytomX Therapeutics Inc.'s CEO.
How many directors are on CytomX Therapeutics Inc.'s board?
CytomX Therapeutics Inc.'s board has 9 directors: Alan Ashworth, Charles S. Fuchs, Elaine Jones V, Halley E. Gilbert, James R. Meyers, Mani Mohindru, Matthew P. Young, Sean A. McCarthy and Zhen Su.
Are CytomX Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, CytomX Therapeutics Inc. insiders made no open-market purchases and sold $1.2 million of shares in 5 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="cytomx-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.